Josemir W. Sander

Epigraph is now entering its ninth year and continues to do well. We strive to disseminate news from the Executive Committee and of epilepsy initiatives from around the world, and this has been recognised by our membership. It was indeed very pleasing for the editorial team to hear, at the Chapters convention in Madrid, how highly regarded Epigraph is by our Chapters. We are always trying to improve and to respond to the expectations of our constituency. For instance, in response to the feedback from the Madrid convention, we have launched a "country focus" feature. This is an opportunity for Chapters to contribute information about epilepsy initiatives in their own country.

It is our intention that each issue of Epigraph is personally delivered to all members. We are getting close to this stage. We now have a complete set of mailing lists for more than 30 countries, and members in these Chapters are receiving their copy by post as soon as it is published. As the compilation of a central database of ILAE members progresses and more accurate contact details for our Chapters are acquired, we hope to be able to deliver a personal copy to all members throughout the world. Each issue of Epigraph is also posted on the ILAE Website and we hope eventually to have an electronic version sent to members who are interested in receiving the publication in this way.

Since its onset, Epigraph has been sponsored by Janssen-Cilag. This support, however, is now coming to an end, and we would like to take this opportunity to thank Janssen-Cilag for their generous unrestricted sponsorship of Epigraph over the last eight years. Novartis, to whom we are very grateful, has agreed to sponsor Epigraph and we look forward to it going from strength to strength under their sponsorship.